The FDA approved the first generic version of Xofluza (baloxavir marboxil) on June 17, clearing Norwich Pharmaceuticals’ single-dose influenza tablet ahead of the 2026–27 flu season.
Generic baloxavir marboxil is approved to treat acute uncomplicated influenza in patients 5 and older who have been symptomatic for no more than 48 hours. It’s also approved for post-exposure prophylaxis for the same age group.
The drug works by inhibiting a viral enzyme called cap-dependent endonuclease, a mechanism distinct from older antivirals such as Tamiflu.
The new medication will offer patients a lower-cost version of the branded Xofluza, a registered trademark of Genentech.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
